References: Li Q, Lin J, Lin Y. Adaptive design implementation in confirmatory trials: methods, practical considerations and case studies. Contemp Clin Trials. 2020;98:106096. (PMID: 10.1016/j.cct.2020.10609632739496)
Day D, Siu LL. Approaches to modernize the combination drug development paradigm. Genome Med. 2016;8(1):1–14. (PMID: 10.1186/s13073-016-0369-x)
Markman TM, Markman M. Cardio-Oncology: mechanisms of cardiovascular toxicity [version 1; peer review: 2 approved]. F1000Research. 2018;7(F1000 Faculty Rev):113. https://doi.org/10.12688/f1000research.12598.1 .
Stone JB, DeAngelis LM. Cancer-treatment-induced neurotoxicity–focus on newer treatments. Nat Rev Clin Oncol. 2016;13(2):92–105. (PMID: 10.1038/nrclinonc.2015.15226391778)
Karakunnel JJ, Bui N, Palaniappan L, Schmidt KT, Mahaffey KW, Morrison B, et al. Reviewing the role of healthy volunteer studies in drug development. J Transl Med. 2018;16(1):1–15. (PMID: 10.1186/s12967-018-1710-5)
Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria JC, Marabelle A. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Ann Oncol. 2016;27(2):214–24. (PMID: 10.1093/annonc/mdv55026578728)
Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, et al. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res. 2006;12(7):1966–9. (PMID: 10.1158/1078-0432.CCR-05-113616609005)
Hobbs BP, Chen N, Lee JJ. Controlled multi-arm platform design using predictive probability. Stat Methods Med Res. 2018;27(1):65–78. (PMID: 10.1177/096228021562069626763586)
Ding Y. A randomized Bayesian optimal phase II design with binary endpoint. J Biopharm Stat. 2023;33(2):151–66. (PMID: 10.1080/10543406.2022.209493835793222)
Li Q, Lin J, Liu M, Wu L, Liu Y. Using surrogate endpoints in adaptive designs with delayed treatment effect. Stat Biopharm Res. 2022;14(4):661–70. (PMID: 10.1080/19466315.2021.1938203)
Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Moura BG, et al. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy. Eur J Cancer. 2021;149:153–64. (PMID: 10.1016/j.ejca.2021.03.01033865201)
Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol. 2018;29(1):84–91. (PMID: 10.1093/annonc/mdx75529228097)
Song G, Ivanova A. Enrollment and stopping rules for managing toxicity requiring long follow-up in phase II oncology trials. J Biopharm Stat. 2015;25(6):1206–14. (PMID: 10.1080/10543406.2015.1086779263839174689581)
Iasonos A, O’Quigley J. Dose expansion cohorts in phase I trials. Stat Biopharm Res. 2016;8(2):161–70. (PMID: 10.1080/19466315.2015.1135185275168484976787)
Ryan EG, Brock K, Gates S, Slade D. Do we need to adjust for interim analyses in a Bayesian adaptive trial design? BMC Med Res Methodol. 2020;20(1):1–9. (PMID: 10.1186/s12874-020-01042-7)
Stallard N, Todd S, Ryan EG, Gates S. Comparison of Bayesian and frequentist group-sequential clinical trial designs. BMC Med Res Methodol. 2020;20(1):1–14. (PMID: 10.1186/s12874-019-0892-8)
Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. CRC Press; 1999.
Litiere S, Collette S, de Vries EG, Seymour L, Bogaerts J. RECIST–learning from the past to build the future. Nat Rev Clin Oncol. 2017;14(3):187–92. (PMID: 10.1038/nrclinonc.2016.19527995946)
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–52. (PMID: 10.1016/S1470-2045(17)30074-8282718695648544)
Li H, Li CW, Li X, Ding Q, Guo L, Liu S, et al. MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1. Gastroenterology. 2019;156(6):1849–61. (PMID: 10.1053/j.gastro.2019.01.25230711629)
Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O’Donnell JS, Szczepanski S, et al. Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy. Immunity. 2017;47(4):789–802. (PMID: 10.1016/j.immuni.2017.09.01229045907)
Lin R, Coleman RL, Yuan Y. TOP: Time-to-event Bayesian optimal phase II trial design for cancer immunotherapy. J Natl Cancer Inst. 2020;112(1):38–45. (PMID: 10.1093/jnci/djz04930924863)
Zhou H, Lee JJ, Yuan Y. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. Stat Med. 2017;36(21):3302–14. (PMID: 10.1002/sim.733828589563)
Ivanova A, Song G, Marchenko O, Moschos S. Monitoring rules for toxicity in phase II oncology trials. Clin Investig. 2015;5(4):373–81. (PMID: 10.4155/cli.15.2)
Thall PF, Simon RM, Estey EH. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol. 1996;14(1):296–303. (PMID: 10.1200/JCO.1996.14.1.2968558211)
Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10. (PMID: 10.1016/0197-2456(89)90015-92702835)
Palmieri DJ, Carlino MS. Immune checkpoint inhibitor toxicity. Curr Oncol Rep. 2018;20(9):1–12. (PMID: 10.1007/s11912-018-0718-6)
Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):1–11. (PMID: 10.1186/s40425-019-0805-8)
Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics. 1995;51(4):1372–83.
Tournoux C, De Rycke Y, Médioni J, Asselain B. Methods of joint evaluation of efficacy and toxicity in phase II clinical trials. Contemp Clin Trials. 2007;28(4):514–24. (PMID: 10.1016/j.cct.2007.01.00817331808)
Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16(1):1–15. (PMID: 10.1186/s12916-018-1017-7)
Stallard N, Hampson L, Benda N, Brannath W, Burnett T, Friede T, et al. Efficient adaptive designs for clinical trials of interventions for COVID-19. Stat Biopharm Res. 2020;12(4):483–97. (PMID: 10.1080/19466315.2020.1790415341919818011600)
Koopmeiners JS, Modiano J. A Bayesian adaptive phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes. Clin Trials. 2014;11(1):38–48. (PMID: 10.1177/174077451350058924082004)
Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, Joseph Mattingly T, et al. The promise of Immuno-oncology: implications for defining the value of cancer treatment. J Immunother Cancer. 2019;7(1):1–11. (PMID: 10.1186/s40425-019-0594-0)
Cai C, Liu S, Yuan Y. A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation. Stat Med. 2014;33(23):4017–28. (PMID: 10.1002/sim.6200248175564435968)
Bassler D, Montori VM, Briel M, Glasziou P, Guyatt G. Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol. 2008;61(3):241–6. (PMID: 10.1016/j.jclinepi.2007.07.01618226746)
No Comments.